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  EVIDENCE-BASED ANSWER 
Colposcopy is the preferred test in the work-up of patients with abnormal cervical cytology: 
• Low-grade squamous intraepithelial lesion (LSIL): mild dysplasia 
• High-grade squamous intraepithelial lesion (HSIL): moderate to severe dysplasia. 
• Atypical squamous cells of undetermined significance (ASC-US) with high-risk human papillo-
mavirus (HPV) DNA 
• Atypical squamous cells, cannot rule out HSIL (ASC-H) 
• Atypical glandular cells (AGC) 
• Adenocarcinoma in situ (AIS) 
Colposcopy is also recommended for patients with symptoms suggestive of cervical cancer (abnormal 
appearance of the cervix, persistent and undiagnosed vaginal discharge or bleeding) regardless of cytology 
results, and in the follow-up of patients previously treated for cervical dysplasia (Grade of Recommendation: 
B). Colposcopy is not recommended for routine cervical cancer screening. 
  EVIDENCE SUMMARY 
The primary role of colposcopy is to identify cervical lesions, allowing directed biopsies to identify invasive 
cancer or its precursors. Although colposcopy has been studied as a primary screening technique, issues of 
cost, accessibility, invasiveness, and low specificity severely limit its usefulness in this role.1 Using histology as 
the gold standard, the sensitivity of colposcopy for cervical abnormalities is high (96%; 95% confidence interval 
[CI], 95%–97%), but the specificity is much lower (48%; 95% CI, 47%–49%).2 This low specificity means that 
more than half of women with no cervical pathology will have an abnormal colposcopy result. The 
corresponding positive and negative likelihood ratios are 2 and 0.1, respectively. Consequently, a normal 
colposcopy result can effectively rule out cervical pathology, thus supporting its role as a diagnostic rather than 
a screening tool. 
While most lesions are found by abnormal cytology, the sensitivity of the Papanicolaou smear ranges from 
30% to 89%.3 Therefore, colposcopy is also indicated for patients with symptoms suggestive of cervical 
dysplasia or cancer (abnormal appearance of the cervix, or persistent and undiagnosed vaginal discharge or 
bleeding), even in the setting of normal cytology.4 
Colposcopy is also indicated for follow-up after treatment of cervical dysplasia. One study5 identified 3 risk 
factors for recurrence of dysplasia after a loop electrocautery excision procedure (LEEP): residual disease at 
either the endocervical or ectocervical margins, and involvement of endocervical glands. The presence of 
these risk factors predicted a recurrence rate of almost 70%.5 Because 8% of the recurrences were missed on 
cytology, the authors recommended colposcopy 6 months after LEEP for patients with these risk factors. 
  RECOMMENDATIONS FROM OTHERS 
The place of colposcopy in the work-up of patients with abnormal cytology is well supported. With the recent 
revision of the Bethesda System by the National Cancer Institute,6 the American Society for Colposcopy and 
Cervical Pathology (ASCCP) held a consensus conference to review the literature and provide evidence-based 
guidelines for management of abnormal cervical cytology.7 Its recommendations on colposcopy are 
summarized in the Table. 
The U.S. Preventive Services Task Force’s 1996 recommendations found insufficient evidence to recommend 
either for or against the use of colposcopy as a screening tool for cervical cancer. Based on high cost and low 
specificity, it recommends against screening colposcopy.8 
 
TABLE 
Recommendations for colposcopy, American Society for Colposcopy and 
Cervical Pathology7 
Cytology 
result 
Recommendation for colposcopy 
Strength of 
recommendation 
ASC-US Preferred for positive high-risk HPV DNA A 
Acceptable for any patient with ASC-US A 
Also acceptable: intensive cytology follow-up 
alone 
A 
Preferred for any immunosuppressed patient B 
ASC-H Preferred for all patients A 
AGC or 
AIS 
Preferred for all patients (include endocervical 
curettage) 
A 
Preferred for those older than 35 years, or 
having atypical endometrial cells, or unexplained 
vaginal bleeding (include endometrial biopsy) 
LSIL Preferred for all patients A 
HSIL 
Preferred for all patients (include endocervical 
curettage) 
A 
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The evaluation of abnormal Pap smear results is a common problem for providers of 
women’s health care. Questions as to which women should be referred for colposcopy 
occur most commonly when the Pap smear shows ASC-US, AGC, or abnormal clinical 
findings. The recent evidence-based guidelines from the ASCCP provide clearer guidance 
as to who needs colposcopy, especially when Pap smear results are minimally abnormal. 
Evaluation of LSIL confirmed by colposcopy and biopsy is another area causing 
confusion. It is reasonable for these patients to be followed with regular Pap smears for up 
to 2 years, as the smears of many women will return to normal without any treatment. I 
usually do not recommend they return for colposcopy unless the Pap smear result 
worsens or does not normalize after 2 years. 
Patients, as well as providers, have many questions regarding HPV testing. Recently, the 
ALTS trial has shown that HPV testing in patients with ASC-US can be useful in 
determining which patients need colposcopy.9 
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